Results 81 to 90 of about 1,112,270 (253)

Formyl Peptide Receptor 2 Activation Ameliorates Dermal Fibrosis and Inflammation in Bleomycin-Induced Scleroderma

open access: yesFrontiers in Immunology, 2019
Systemic sclerosis is a profibrotic autoimmune disease mediated by the dysregulation of extracellular matrix synthesis. Formyl peptide receptor 2 (Fpr2) is a G protein-coupled receptor that modulates inflammation and host defense by regulating the ...
Gyu Tae Park   +7 more
doaj   +1 more source

Comparative Transcriptional Profiling of Key Macrophage and Fibroblast Subpopulations in Rheumatoid Arthritis–Associated Lung Disease

open access: yesArthritis &Rheumatology, EarlyView.
Objective Rheumatoid arthritis (RA) often involves extra‐articular complications, including interstitial lung disease (ILD) and/or pulmonary nodules. Transcriptomic profiling of lung tissue provides the opportunity to directly assess cell‐specific gene expression and corresponding pathway activation in different types of rheumatoid lung disease ...
Tracy Tabib   +8 more
wiley   +1 more source

Localized scleroderma – current treatment options

open access: yes, 2017
Localized scleroderma (morphea) is a connective tissue disease that affects the skin, subcutaneous tissue and underlying tissues including the fasciae, muscles and bones. The treatment of localized scleroderma depends on the clinical form of the disease,
Małgorzata Michalska-Jakubus   +2 more
core   +1 more source

Intravenous iloprost in the combination therapy of vascular disorders in patients with systemic connective tissue diseases

open access: yesСовременная ревматология, 2013
Systemic connective tissue diseases, systemic scleroderma in particular, constitute a group of diseases in which vascular disorders underlying diverse clinical manifestations are one of the pathogenetic components.
Aleksandr Vitalyevich Volkov   +1 more
doaj   +1 more source

Control of Fibrosis in Systemic Scleroderma.

open access: yesJournal of Investigative Dermatology, 1993
Scleroderma is characterized by an excessive deposition of collagen in all involved organs. This is due to an overproduction of extracellular matrix (ECM) molecules following induction of gene expression, whereas there is no evidence that the composition of the connective tissue matrix is altered.
Mauch, Cornelia   +5 more
openaire   +2 more sources

Outcomes in Progressive Pulmonary Fibrosis in Systemic Autoimmune Rheumatic Diseases: Real‐World Data From the ILD‐PRO Registry

open access: yesArthritis &Rheumatology, EarlyView.
Objective We evaluated baseline characteristics, treatment patterns, and outcomes in patients with systemic autoimmune rheumatic disease–associated progressive pulmonary fibrosis (SARD‐PPF) and evaluated whether outcomes differed by SARD subtype. Methods The ILD‐PRO Registry is a prospective multicenter US registry of patients with PPF.
Sonali J. Bracken   +7 more
wiley   +1 more source

CARDIAC INVOLVEMENT IN IRAQI PATIENTS WITH SYSTEMIC SCLEROSIS (SCLERODERMA).

open access: yes, 2018
Background: Systemic sclerosis (Scleroderma) is a chronic multisystem disease of unknown etiology, has been considered a disease of metabolic disorder of connective tissue. Methodology: A case control study.
Mustafa Al-Izzi.   +1 more
core   +1 more source

DIAGNOSTIC VALUE OF CERULOPLASMIN IN SYSTEMIC SCLERODERMA

open access: yesМедицинская иммунология, 2019
Objective of study: refining immune diagnostics of systemic scleroderma through determining ceruloplasmin antibodies, its amount and enzymatic activity, as well as control of effectiveness of therapy with ceruloplasmin-based immobilized ...
O. I. Emelyanova   +3 more
doaj   +1 more source

Telangiectasia in Systemic Sclerosis Is a Marker of Increased Disease Morbidity and Mortality: Analyses From the Australian Scleroderma Cohort Study. [PDF]

open access: yesAustralas J Dermatol
ABSTRACT This Australian retrospective cohort analysis of 1977 patients investigates and expands on correlates of telangiectasia in systemic sclerosis to determine whether this cutaneous sign is a potential surrogate marker for disease progression and prognosis.
Lai VWY   +15 more
europepmc   +2 more sources

Abatacept Reduces CD319+ (SLAMF7) Cytotoxic T Cells and Cytokine Production in Systemic Sclerosis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Systemic sclerosis (SSc) is characterized by immune dysregulation and fibrosis. We investigated whether abatacept modulates CD319/SLAMF7‐expressing cytotoxic T cells implicated in diffuse cutaneous SSc. Methods In this ancillary ASSET trial analysis, peripheral blood mononuclear cells from 67 participants were analyzed at baseline and months ...
Mikel Gurrea‐Rubio   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy